INTRODUCTION
Blood samples were collected and analyzed for plasma IL-1ra levels in 55 patients with UC and 41 with CD. The diagnoses were based on characteristic clinical, endoscopic, radiologic and histologic criteria. Disease activity of UC was analyzed according to the criteria of Truelove and Wills and was classified as inactive, mild, moderate, or severe [18] . Disease activity of CD was assessed by the score of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) in which a score of 0-1 was defined as inactive disease and a score of 2 or greater as active disease [ 19] . The characteristics of the patient population are given in Table 1 .
Twenty-four volunteers with an age range and sex distribution similar to the IBD patients served as normal controls. The disease control group comprised nine patients with infectious colitis and two patients with ischemic colitis. This project was performed according to the Helsinki Declaration and informed consent was obtained from every participant.
ELISA for IL-1ra IL-1ra was measured by a sandwich ELISA developed by Amersham International plc (Biotrak, UK) using a mouse anti-human IL-1ra monoclonal antibody for capture and a goat anti-human IL-lra polyclonal antibody for detection. 
RESULTS

Plasma levels of IL-1ra
The plasma IL-lra levels in patients with active UC and CD were significantly higher than those of healthy controls (P<0.001 for both). There was no significant difference in IL-Ira levels between active UC and CD. The levels in patients with inactive UC and CD were significantly lower than in patients with active disease (P<0.01 and P<0.05, respectively), but were higher than in normal controls (P<0.005 for both). The levels in disease controls were significantly higher than in healthy controls (P<0.001) (Fig. 1) . The analysis of paired samples showed a significant reduction of the plasma IL-Ira level in every patient with either form of IBD after clinical improvement (P<0.05 for both) (Fig. 2) .
Relationship of IL-Ira or sIL-2R plasma levels to clinical and laboratory parameters
There was a statistical association between the IL-lra level and clinical parameters in patients with (Fig. 3) . A similar association was observed between the sIL-2R level and clinical parameters (UC, P<0.0001; CD, r=0.618, P<0.001) (data not shown). Table 2 summarizes the correlation coefficients and significance values between plasma ILira levels and each indicated laboratory parameter.
There was a significant correlation between the ILIra level and laboratory parameters, such as CRP or leukocyte count, in patients with these diseases. In addition, a comparison between these parameters and plasma sIL-2R levels in the same patients was also shown.
DISCUSSION
This study shows that patients with active IBD had increased circulating levels of IL-ira compared with healthy controls. The levels were lower in patients with inactive IBD than in patients with active disease, but remained higher than in healthy controls, suggesting either the presence of underlying immunologic activation or slow clearance of this circulating protein. However, the latter is probably unlikely since recent longitudinal studies in patients undergoing surgery [20] or during experimental endotoxemia [21] have demonstrated the rapid restoration of IL-lra to its baseline level after the initial elevation of circulating IL-1ra.
We next compared the circulating IL-1 ra level to clinical and laboratory parameters of disease activity. We found a statistical association between IL-ira levels and clinical disease activity or laboratory parameters such as CRP or leukocyte count in both diseases. We also confirmed the significance of the correlation of circulating sIL-2R levels with clinical disease activity and some of the laboratory parameters, as shown in previous studies [22, 23] . These results may be of interest since there is great need for a relevant marker of IBD activity. Although the mechanism for regulating the ILira release in IBD is unknown, several stimuli, such as IL-4 [24], IL-10 [25] and granulocyte-macrophage colony-stimulating factor [26] , have been shown to stimulate the production of IL-ira in vitro. These facts, together with recent reports describing the presence of these cytokines in IBD [3, 5] , suggest that these cytokines may in part influence IL-1 ra release in vivo. It is of interest that the acute phase proteins, CRP and a 1-antitrypsin, are potent inducers of IL-ira [27] . In the present study, we found a high correlation between CRP and IL-ira levels, suggesting that such unique induction of this antagonist also occurs in vivo. Moreover, this suggests that increased circulating acute phase proteins contribute indirectly to systemic down-regulation of active inflammation, as suggested previously in animal models [28] . These results suggest that circulating IL-lra limits inflammatory disease, however, such concentrations are probably insufficient to overwhelm the exaggerated IL-I production since at least a 10,000-fold molar excess of IL-lra is required to prevent the action of IL-1 in vi vo [11] .
In conclusion, the results of the present study suggest that the plasma IL-ira level in patients with IBD may e a useful marker of disease activity.
